COVID-19: Anxiety about the effect of Chinese-made corona vaccine: Bahrain, UAE
-“Re-inoculation” of Pfizer vaccine-
Doubts about China National Pharmaceutical Vaccines:
“Uncertainty about the effectiveness of vaccines” manufactured by China National Pharmaceutical Group Corporation is increasing.
Bahrain Vaccination Rate:
Bahrain has the highest vaccination coverage for the new coronavirus.
However, “the number of infected people is increasing rapidly with overwhelming momentum.”
Additional vaccine:
Bahrain has already completed two doses of China National Pharmaceutical vaccine on June 3.
However, it has revealed that it will “start booster shots” of the Pfizer-Germany BioNTech vaccine.
Bahrain Ministry of Health:
We are calling for booster vaccinations for those who have received a second dose of China National Pharmaceutical vaccine.
Of those who are 6 months old
For people at high risk of infection
Additional inoculation of Pfizer vaccine,
Bahrain’s death toll surge:
The “percentage of people who have completed vaccination in Bahrain” has reached 50%.
The policy was changed because “the number of deaths per 100,000 population far exceeded that of India.”
UAE
United Arab Emirates (UAE) has already launched booster shots.
Seychelles
Seychelles is also considering launching a booster shot.
WHO also approves made in China:
China National Pharmaceutical Vaccine
China National’s vaccine was approved for emergency use by WHO in early May.
Chinese Sinovac Vaccine
The Chinese Sinovac vaccine has also been approved for emergency use by WHO.
However, “both concerns about effectiveness” were expressed.
Effectiveness concerns:
In the vaccine efficacy verification of two Chinese companies,
Insufficient clinical data required,
The published data is incomplete,
The Chinese government is using the vaccine politically,
The main reason is that the above problems have been pointed out.
Analysis of Chinese vaccines:
At the end of May, we analyzed the results of a phase 3 clinical trial of a Chinese vaccine.
Peer-reviewed treatises analyzed:
The efficacy of the two vaccines is 73% and 78%, respectively.
Subjects of clinical trials:
However, the problem is that “the target of Chinese vaccines and clinical trials is young and healthy men.”
It does not include people with chronic illnesses, women or the elderly.
Forbes JAPAN